OMS721 (narsoplimab)

BIOLOGICAL2 trials

Sponsors

Omeros Corporation

Conditions

Atypical Hemolytic Uremic SyndromeC3GIgANLNMNThrombotic Microangiopathies

Phase 2

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

TerminatedNCT02682407

Omeros CorporationC3G, IgAN, LN +1

Start: 2016-03-10End: 2020-08-25Updated: 2026-03-30

Phase 3

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

TerminatedNCT03205995

Omeros CorporationAtypical Hemolytic Uremic Syndrome, Thrombotic Microangiopathies

Start: 2018-05-02End: 2021-02-02Updated: 2025-12-10

Related Papers

POS-132 TRIAL DESIGN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NARSOPLIMAB SAFETY AND EFFICACY IN IGA NEPHROPATHY (ARTEMIS-IGAN)

Kidney International Reports2022-02-015 citations